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Abstract
This issue marks the end of the 10-year anniversary of Neoplasia where we have seen exciting growth in both
number of submitted and published articles in Neoplasia. Neoplasia was first published in 1999. During the past
10 years, Neoplasia has dynamically adapted to the needs of the cancer research community as technologies have
advanced. Neoplasia is currently providing access to articles through PubMed Central to continue to facilitate rapid
broad-based dissemination of published findings to the scientific community through an Open Access model. This
has in part helped Neoplasia to achieve an improved impact factor this past year, demonstrating that the manu-
scripts published by Neoplasia are of great interest to the overall cancer research community. This past year, Neo-
plasia received a record number of articles for review and has had a 21% increase in the number of published articles.
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Overview
During the past 3 years (2006–2008), Neoplasia has shown strong
growth as evidenced in the number of articles published. As shown
in Figure 1, the percentage of articles published in Neoplasia increased
by 6% in 2007 and further increased by an astounding 21% in 2008.
Manuscripts published in these pages continue to be of the utmost
high quality and cover a broad range of research topics and reviews
from many different and exciting areas of cancer research. Shown
in Table 1 are examples of articles previously published which have
been sorted by general topic area for the 2006–2008 publication time
frame. Whereas many articles could be classified in several of these
categories, it is evident that Neoplasia provides its readership with a
broad coverage of the many exciting discoveries during the past year.
Neoplasia continues to differentiate itself from other journals in
many areas. One key example is that Neoplasia provides immediate
open access to all of its published articles at the time of publication
through PubMed Central. This policy allows for all of the articles
published by Neoplasia to be accessible immediately to the worldwide
cancer research communities and to patients interested in keeping
up-to-date with the latest developments, which may affect their treat-
ment decisions. This feature also provides authors’ research findings
available to the largest possible readership ensuring that articles pub-
lished in Neoplasia will have significant impact. One metric of the
success of Open Access can be found in the Thomson Scientific Im-
pact Factor, which, for Neoplasia, has increased from 4.9 in 2006 to
5.7 in 2007, revealing both the high quality and impact of articles
Figure 1. A plot of the percent increase in the number of articles
published in Neoplasia from 2006 to 2008. For each year, the bar
graph indicates the percentage increase over the prior year. Note a
major jump in the percentage of published articles occurred in
2008, which was 21% more than that in the previous year.
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published by Neoplasia and the increased impact in the cancer field as
judged by the escalating number of citations by other scientists.
In conclusion, Neoplasia has successfully adapted to the needs of
the cancer research community by implementing leading-edge tech-
nological changes including online peer review and electronic hosting
of articles on PubMed Central, which now provides for instant and
Open Access for all articles published within our pages.
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